Company profile
Q32 BIO INC.
NASDAQ:QTTBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BEMPIKIBART | phase2 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06018428 | phase2 | active_not_recruiting | 2023-09-12 | 2026-06-01 | Q32 Bio Inc. | A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) |
| NCT05509023 | phase2 | active_not_recruiting | 2022-09-30 | 2024-12-01 | Q32 Bio Inc. | Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) |
| NCT04485481 | phase1 | completed | 2020-09-08 | 2022-01-12 | Q32 Bio Inc. | Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers |
FDA applications (0)
No records yet.